← 홈

ADC

1,068개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,068개
ADCBiologicstaleByondis B.V.Phase 1

BYON4413 (BYON4413)

Relapsed / Refractory AML; Relapsed / Refractory MDS · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Ivonescimab (Becotatug Vedotin Combined with Ivonescimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Penpulimab (Becotatug Vedotin Combined with Penpulimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleShanghai Ninth People's Hospita…Phase 2

sacituzumab govitecan (Trodelvy, Becotatug Vedotin or Sacituzumab Tirumotecan)

Adenoid Cystic Carcinoma of the Head and Neck; SBRT · Adenoid Cystic Carcinoma of the Head and

#AdenoidCysticCarcinomaoftheHeada#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleChildren's Cancer Group, ChinaPhase 3

Bedamustine (Bedamustine)

Classical Hodgkin Lymphoma; Child · Classical Hodgkin Lymphoma

#ClassicalHodgkinLymphoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages)

AL Amyloidosis; Amyloidosis · AL Amyloidosis

#ALAmyloidosis#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleFudan UniversityPhase 2

Benmelstobart (Benmelstobart)

Breast Neoplasm; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Berzosertib (Berzosertib)

HRD Cancer; SCLC · HRD Cancer

#HRDCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleAmgenPhase 2

Blinatumomab and Inotuzumab Ozogamicin (Blinatumomab and Inotuzumab Ozogamicin)

Acute Lymphoblastic Leukemia; Immunotherapy · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleSeagenPreclinical

brentuximab vedotin (Adcetris, Brentuximab Vedotin Plus CHP)

CD30-Positive Peripheral T-Cell Lymphoma · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleSeagenPhase 1

brentuximab vedotin (Adcetris, Brentuximab vedotin and rifampicin)

Hodgkin Lymphoma; Anaplastic Large-cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-AVD-R 1 and 2: COHORT IIa (Bv-AVD-R 1 and 2: COHORT IIa)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NAVD-R, Cycle 1-2 (Bv-NAVD-R, Cycle 1-2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NVD-R, Cycle 1-2 (Bv-NVD-R, Cycle 1-2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NVD-R, Cycle 1-4 RER (Bv-NVD-R, Cycle 1-4 RER)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NVD-R, Cycle 1-4 SER (Bv-NVD-R, Cycle 1-4 SER)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleFudan UniversityPhase 2

C1: SHR-A1811 (C1: SHR-A1811)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleFudan UniversityPhase 2

C2: SHR-A1811 with BP102 (C2: SHR-A1811 with BP102)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING

38 / 54 페이지

← 이전다음 →